TriAltus Bioscience (AL, USA) has announced the launch of a new affinity chromatography resin for the cl7/im7 protein purification system, with double the binding capacity of the original resin for the single-step protein purification system.
Novel microfluidic impedance cytometry device: simultaneous measurement of single-cell lateral position and biophysical properties
A research team from Singapore University of Technology and Design (Singapore) has developed a microfluidic impedance flow cytometry device that could be capable of simultaneously measuring the lateral position and biophysical properties of single cells.
Researchers based at the University of Toronto (ON, CA) have developed a microfluidic device that could be used to separate malignant plasma cells from healthy red blood cells. The device could have the potential to detect and monitor blood cancer.
American biotechnology product development company, Thermo Fisher Scientific (MA, USA), has announced the official opening of a Customer Solution Center in Shanghai, China.
Researchers from the University of Texas Southwestern Medical Center (TX, USA) have identified a biomarker blood test that could identify individuals with early-stage heart disease in need of treatment.
Advancing novel biomarker identification: Thermo Fisher Scientific collaborate with Owlstone Medical
Thermo Fisher Scientific (MA, USA) have announced a collaborative partnership with Owlstone Medical (Cambridge, UK). The partnership will work towards the advancement of early cancer and disease diagnosis through the discovery and validation of novel biomarkers.
Aston University (Birmingham, UK) has announced the installation of the Waters (MA, USA) SELECT SERIES Cyclic™ ion mobility spectrometry mass spectrometer, the first commercial research installation of an instrument of its kind.
BioAgilytix (NC, USA), a provider of large-molecule bioanalytical testing services, has announced the acquisition of the Boston-based CRO, Cambridge Biomedical (MA, USA), which also specializes in large-molecule bioanalysis.
Researchers have analyzed flotillin levels in samples from individuals with and without Alzheimer’s disease (AD) and determined that serum flotillin levels are negatively associated with brain amyloid deposition. Flotillin could serve as a biomarker to estimate brain amyloid deposition, potentially aiding the early diagnosis of AD.
Novel artificial intelligence tool could revolutionize bioanalytical data review for precision drug development
Specialist in artificial intelligence-enabled solutions, Ariadne Software (PA, USA), announces the launch of Red Thread™, an innovative tool that could revolutionize bioanalytical data review for precision drug development.